Jump to content

Pimozide

From Pharmacopedia
Revision as of 15:06, 14 May 2026 by MediaWiki default (talk | contribs) (Assign pharmacological categories from List_of_CNS-active_medicines)
Antipsychotic, Neuroleptic
Pimozide
Orap

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Interactions

Pharmacogenomic + mechanism interactions2 edges
Pharmacogenomic guideline recommendationsCPIC and Dutch Pharmacogenetics Working Group clinical guidelines
Phenotype:CYP2D6 poor metabolizer dose reduce 50 DPWG 60 / 100
DPWG guideline: Patients who are CYP2D6 intermediate metabolizers should be given no more than 80% of the standard maximum dose of pimozide while patients who are CYP2D6 poor metabolizers should be given no more than 50% of the standard maximum dose.
Phenotype:CYP2D6 intermediate metabolizer dose reduce 50 DPWG 60 / 100
DPWG guideline: Patients who are CYP2D6 intermediate metabolizers should be given no more than 80% of the standard maximum dose of pimozide while patients who are CYP2D6 poor metabolizers should be given no more than 50% of the standard maximum dose.

Patient experience

No patient-experience reports yet.

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
Antipsychotic, Neuroleptic
Common uses
Pharmacy
Pharmacology
Purported mechanism
Diphenylbutylpiperidine D2 antagonist